Sanofi India Limited

SANOFI

INE058A01010

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 11:00:56 05/07/2024 BST			5-day change	1st Jan Change
6,582 ^INR	+0.09%		+1.36%	-18.41%

07-03	Sanofi India Limited Announces Resignation of Shalini Menon, General Medicines Medical Head and India Medical Lead, Effective July 5, 2024	CI
06-21	Sanofi India Limited Appoints N. Suresh Babu as Sales & Customer Engagement Head Diabetes, Effective July 1, 2024	CI

Sanofi India Limited Announces Resignation of Shalini Menon, General Medicines Medical Head and India Medical Lead, Effective July 5, 2024

July 03, 2024 at 02:17 pm

Sanofi India Limited announced the resignation of Dr. Shalini Menon, General Medicines Medical Head and India Medical Lead and indicated that her last working day would be determined mutually, please be advised that her last working day will be 5th July 2024. Consequently, she will also cease to be Senior Management Personnel of the Company as of that date.

Latest news about Sanofi India Limited

Sanofi India Limited Announces Resignation of Shalini Menon, General Medicines Medical Head and India Medical Lead, Effective July 5, 2024	07-03	CI
Sanofi India Limited Appoints N. Suresh Babu as Sales & Customer Engagement Head Diabetes, Effective July 1, 2024	06-21	CI
Sanofi India Limited completed the Spin-Off of Sanofi Consumer Healthcare India Limited.	06-16	CI
Transcript : Sanofi India Limited, Q1 2024 Earnings Call, May 16, 2024	05-16
Sanofi India Limited Announces Resignation of Shalini Menon as General Medicines Medical Head and India Medical Lead	05-14	CI
Sanofi India Limited Declares Final Dividend for the Financial Year Ended December 31, 2023	05-14	CI
Sanofi India's Net Profit Slides in Q1	05-14	MT
Sanofi India Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Sanofi India Limited Receives an Order Passed by the Office of the Assistant Commissioner of State Tax, State Goods and Services Tax Department, Taxpayer Services Circle Kadavanthra At Tripunithura	05-06	CI
Sanofi India Limited Announces Appointment of Flovie Martins as Head of Corporate Communications and Corporate Social Responsibility	04-14	CI
Sanofi India Limited Announces Resignation of Marc-Antoine Lucchini as Non-Executive Director from the Board of Directors, Member of the Nomination and Remuneration Committee	03-28	CI
Cipla to Distribute Sanofi's CNS Product Line in India	03-27	MT
Sanofi India Limited, Sanofi Healthcare India Private Limited and Cipla Limited Announce an Exclusive Partnership	03-26	CI
Sanofi India Limited and Emcure Pharmaceuticals Announces Exclusive Distribution Partnership to Broad Broadline Reach of Sanofi's Cardiovascular Brands	03-13	CI
Transcript : Sanofi India Limited, Q4 2023 Earnings Call, Feb 26, 2024	02-26
Sanofi India Limited Recommends Final Dividend for the Financial Year Ended 31St December 2023, Payable on or After 24 May 2024	02-23	CI
Sanofi India Limited Declares Interim Dividend for the Financial Year Ended 31St December, 2023, Payable on or After 20 March, 2024	02-23	CI
Sanofi India Limited Reports Earnings Results for the Full Year Ended December 31, 2023	02-23	CI
Sanofi India Limited Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-23	CI
Sanofi India Limited Appoints Radhika Shah as Head of Legal, Effective 15 January 2024	01-10	CI
Sanofi Sees Improvement in Trial Results of Cancer Drug Sarclisa	12-11	DJ
Trending : Merck's Multiple Sclerosis Drug Misses Expectations in Late-Stage Trials	12-06	DJ
Transcript : Sanofi India Limited, Q3 2023 Earnings Call, Nov 15, 2023	11-15
Sanofi India's CFO Steps Down	11-09	MT
Sanofi India Limited Announces the Resignation of Vaibhav Karandikar as Whole-Time Director	11-08	CI

Chart Sanofi India Limited

Duration

Period

More charts

Company Profile

Sanofi India Limited is an India-based company, which is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. The Company produces pharmaceutical formulations, dosage forms and offer a range of medicines across various therapeutic areas. Its product portfolio is focused on five therapeutic areas: diabetes, epilepsy, cardiology, allergy and pain care. In the diabetes area, the Company has an insulin portfolio under the brand name of Lantus, which helps in controlling high blood sugar in adults and children with diabetes mellitus. It also provides Toustar pen, along with dedicated Toujeo cartridges, addressing the need for a reusable delivery device. Combiflam, its product, helps to reduce pain and inflammation in conditions like headache, muscle and joint pain, and also reduces fever. Its brands also include Cardace, Allegra, Avil and Frisium. The Company has its own manufacturing facility in Goa. It has around 12 contract manufacturing organizations.

Sector

Pharmaceuticals

Calendar

22/07/2024 - Q2 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Sanofi India Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SANOFI INDIA LIMITED	-18.41%	1.82B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+24.53%	45.07B
OTSUKA HOLDINGS CO., LTD.	+30.99%	23.39B
SANDOZ GROUP AG	+24.13%	16.08B
CIPLA LIMITED	+21.15%	14.6B
ZYDUS LIFESCIENCES LIMITED	+68.67%	14.01B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-13.29%	6.38B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+13.53%	5.64B

Generic Pharmaceuticals